Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
Thorsten Stiewe, Tali E. Haran
Drug Resistance Updates (2018) Vol. 38, pp. 27-43
Closed Access | Times Cited: 118

Showing 1-25 of 118 citing articles:

Targeting mutant p53 for cancer therapy: direct and indirect strategies
Jiahao Hu, Jiasheng Cao, Win Topatana, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 361
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
Eliran Kadosh, Irit Snir-Alkalay, Avanthika Venkatachalam, et al.
Nature (2020) Vol. 586, Iss. 7827, pp. 133-138
Open Access | Times Cited: 289
The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review
Jin Zhou, Qian Yi, Liling Tang
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 256
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Luciana Mosca, Andrea Ilari, Francesco Fazi, et al.
Drug Resistance Updates (2021) Vol. 54, pp. 100742-100742
Closed Access | Times Cited: 227
Hypoxia as a driver of resistance to immunotherapy
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez-Ruíz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 174
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification
Bowen Li, Jingwen Jiang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100720-100720
Closed Access | Times Cited: 141
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents
Enrique Domínguez‐Álvarez, Bálint Rácz, Małgorzata Anna Marć, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100844-100844
Open Access | Times Cited: 71
Evolutionary trajectories of small cell lung cancer under therapy
Julie George, Lukas Maas, Nima Abedpour, et al.
Nature (2024) Vol. 627, Iss. 8005, pp. 880-889
Open Access | Times Cited: 44
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Bin Song, Ping Yang, Shuyu Zhang
Cancer Communications (2024) Vol. 44, Iss. 3, pp. 297-360
Open Access | Times Cited: 29
Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer
Ana Podolski-Renić, Ana Čipak Gašparović, Andreia Valente, et al.
European Journal of Medicinal Chemistry (2024) Vol. 270, pp. 116363-116363
Closed Access | Times Cited: 23
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Oleg Timofeev, Philippe Giron, Steffen Lawo, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 21
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations
Julianne Funk, Maria Klimovich, Daniel Drangenstein, et al.
Nature Genetics (2025) Vol. 57, Iss. 1, pp. 140-153
Open Access | Times Cited: 8
Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Xin Cao, Jiayun Hou, Quanlin An, et al.
Drug Resistance Updates (2019) Vol. 49, pp. 100671-100671
Closed Access | Times Cited: 141
Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids
Qingmei Ye, Kai Liu, Qun Shen, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 127
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Nir Shahar, Sarit Larisch
Drug Resistance Updates (2020) Vol. 52, pp. 100712-100712
Closed Access | Times Cited: 124
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
Lingyue Gao, Zhuo‐Xun Wu, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2021) Vol. 57, pp. 100770-100770
Closed Access | Times Cited: 96
Revealing a human p53 universe
Thuy‐Ai Nguyen, Sara A. Grimm, Pierre R. Bushel, et al.
Nucleic Acids Research (2018) Vol. 46, Iss. 16, pp. 8153-8167
Open Access | Times Cited: 90
Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance
Andreia Valente, Ana Podolski-Renić, Isabella Poetsch, et al.
Drug Resistance Updates (2021) Vol. 58, pp. 100778-100778
Open Access | Times Cited: 76
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma
Manfei Pi, Huixian Kuang, Chunyan Yue, et al.
Drug Resistance Updates (2022) Vol. 61, pp. 100822-100822
Closed Access | Times Cited: 58
Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer
Yang Yang, Hongyu Yuan, Lianmei Zhao, et al.
Cell Death and Differentiation (2022) Vol. 29, Iss. 11, pp. 2177-2189
Open Access | Times Cited: 57
The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications
Philippe Icard, Luca Simula, Ludovic Fournel, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100852-100852
Open Access | Times Cited: 40
Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm
Matthias R. Bauer, Andreas Krämer, Giovanni Settanni, et al.
ACS Chemical Biology (2020) Vol. 15, Iss. 3, pp. 657-668
Open Access | Times Cited: 63
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer
Gu Xiao, Devon Lundine, George K. Annor, et al.
Cancer Research (2019) Vol. 80, Iss. 3, pp. 394-405
Open Access | Times Cited: 61
Epigenetic enzyme mutations as mediators of anti-cancer drug resistance
Sihong Chen, Yingxi Zhao, Shougeng Liu, et al.
Drug Resistance Updates (2022) Vol. 61, pp. 100821-100821
Closed Access | Times Cited: 33
Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C
Joseph R. Stephenson Clarke, Leon Douglas, Patrick J. Duriez, et al.
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 11, pp. 1169-1180
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top